Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,162,302 papers from all fields of science
Search
Sign In
Create Free Account
cyclohexyl methylphosphonofluoridate
Known as:
GF cpd
, CMPF ester
, CF Me ester
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Nerve Agents
Organophosphorus Compounds
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Molecular aspects of the reactivation process of acetylcholinesterase inhibited by cyclosarin
K. Matos
,
D. T. Mancini
,
E. Cunha
,
T. C. França
,
Teodorico C. Ramalho
2011
Corpus ID: 97227693
®® para avaliar as constantes cineticas de associacao e reativacao de oximas, em relacao a resultados in vitro previamente…
Expand
Highly Cited
2010
Highly Cited
2010
In vivo reactivation by oximes of inhibited blood, brain and peripheral tissue cholinesterase activity following exposure to nerve agents in guinea pigs.
T. Shih
,
Jacob W. Skovira
,
John C. O’Donnell
,
J. McDonough
Chemico-Biological Interactions
2010
Corpus ID: 10504063
2010
2010
Oxime K027: novel low-toxic candidate for the universal reactivator of nerve agent- and pesticide-inhibited acetylcholinesterase
K. Kuča
,
K. Musílek
,
D. Jun
,
M. Pohanka
,
K. Ghosh
,
M. Hrabinová
Journal of Enzyme Inhibition and Medicinal…
2010
Corpus ID: 39631065
Oxime K027 is a low-toxic bisquaternary compound originally developed as a reactivator of acetylcholinesterase (AChE) inhibited…
Expand
2009
2009
A Comparison of neuroprotective efficacy of newly developed oximes (K203, K206) and commonly used oximes (obidoxime, HI-6) in tabun-poisoned rats
J. Kassa
,
J. Karasova
,
L. Vašina
,
J. Bajgar
,
K. Kuča
,
K. Musílek
Drug and chemical toxicology (New York, N.Y. )
2009
Corpus ID: 21746752
The neuroprotective effects of newly developed oximes (K203, K206) and commonly used oximes (obidoxime, HI-6) in combination with…
Expand
2008
2008
Reactivation of DFP- and paraoxon-inhibited acetylcholinesterases by pyridinium oximes.
K. Oh
,
N. Park
,
N. Park
,
K. Kuča
,
D. Jun
,
Young-Sik Jung
Chemico-Biological Interactions
2008
Corpus ID: 5318831
Highly Cited
2007
Highly Cited
2007
Reactivation of organophosphate‐inhibited human AChE by combinations of obidoxime and HI 6 in vitro
F. Worek
,
Nadine Aurbek
,
H. Thiermann
Journal of Applied Toxicology
2007
Corpus ID: 23783538
Highly toxic organophosphorus‐type (OP) chemical warfare agents (nerve agents) and OP pesticides may be used by terrorists and…
Expand
2007
2007
Asymmetric fluorogenic organophosphates for the development of active organophosphate hydrolases with reversed stereoselectivity.
G. Amitai
,
R. Adani
,
+6 authors
H. Meshulam
Toxicology
2007
Corpus ID: 19829916
2005
2005
Evaluation of the toxicity, pathology, and treatment of cyclohexylmethylphosphonofluoridate (CMPF) poisoning in rhesus monkeys
I. Koplovitz
,
V. Gresham
,
L. W. Dochterman
,
A. Kaminskis
,
J. Stewart
Archives of Toxicology
2005
Corpus ID: 28950583
Cyclohexylmethylphosphonofluoridate (CMPF) is an organophosphate cholinesterase inhibitor with military significance. The purpose…
Expand
2005
2005
New quaternary pyridine aldoximes as casual antidotes against nerve agents intoxications.
K. Kuča
,
L. Bartošová
,
+4 authors
G. Kunešová
Biomedical papers of the Medical Faculty of the…
2005
Corpus ID: 16180366
In this work, the ability of four newly synthesized oximes--K005 (1,3-bis(2-hydroxyiminomethylpyridinium) propane dibromide…
Expand
2002
2002
Low-Level Cyclosarin (GF) Vapor Exposure in Rats: Effect of Exposure Concentration and Duration on Pupil Size
R. Mioduszewski
,
J. Manthei
,
R. Way
,
D. Burnett
,
B. Gaviola
2002
Corpus ID: 94448602
Abstract : The probability of cyclo-sarin (GF) vapor-induced miosis (defined as a post-exposure pupil diameter 50% or less of the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE